Johnson & Johnson and Halozyme Therapeutics, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Companies

In the world of pharmaceuticals, Johnson & Johnson and Halozyme Therapeutics, Inc. present a fascinating study in contrasts. Over the past decade, from 2014 to 2023, these two companies have demonstrated markedly different approaches to their Selling, General, and Administrative (SG&A) expenses.

Johnson & Johnson: A Steady Giant

Johnson & Johnson, a titan in the industry, has consistently maintained its SG&A expenses around the $20 billion mark annually. This stability reflects its robust market position and strategic investments in maintaining its global operations.

Halozyme Therapeutics: A Dynamic Challenger

Conversely, Halozyme Therapeutics has shown a dynamic growth trajectory, with SG&A expenses increasing by over 300% from 2014 to 2023. This surge underscores its aggressive expansion and investment in innovation.

These spending patterns highlight the diverse strategies employed by established giants and emerging challengers in the pharmaceutical sector.